

Summary of Product Characteristics for Pharmaceutical Products

1. Name of the medicinal product

Vonofix 10 Tablet
(Vonoprazan Tablets, 10 mg)

2. Qualitative and quantitative composition

Each tablet contains Vonoprazan 10 mg.

There are no excipients of known effect in this formulation.

For a full list of excipients, see section 6.1.

3. Pharmaceutical form

Oral tablet.

4. Clinical particulars

4.1 Therapeutic indications

Vonofix 10 Tablet is indicated for the:

Treatment of gastric ulcer (GU).

Treatment of duodenal ulcer (DU).

Treatment of reflux esophagitis (RE) (erosive esophagitis, EE).

Maintenance treatment of reflux esophagitis (erosive esophagitis) in patients with repeat recurrence and relapse of the condition. The duration of administration in the long-term efficacy clinical Study OCT-001 is up to 52 weeks.

Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration.

Adjunct to *Helicobacter pylori* eradication associated with: gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early stage cancer, or *Helicobacter pylori* gastritis.

4.2 Posology and method of administration

Posology

Adults

Gastric ulcer

The usual dose is 20 mg of vonoprazan once a day. Administration should be limited to 8 weeks.

Duodenal ulcer

The usual dose is 20 mg of vonoprazan once a day. Administration should be limited to 6 weeks.

Reflux esophagitis (erosive esophagitis)

The usual dose is 20 mg of vonoprazan once a day. Administration should be limited to 4 weeks. However, when the effect is insufficient, treatment may be continued for up to 8 weeks. In addition, for the maintenance of healing of reflux esophagitis in patients with repeat recurrence and

relapse of the condition, a dose of 10 mg is administered once a day; however, when the efficacy is inadequate, a dose of 20 mg may be administered once a day. The duration of administration in the long-term efficacy clinical Study OCT-001 is up to 52 weeks.

Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration

The usual dose is 10 mg of vonoprazan once a day.

Adjunct to Helicobacter pylori eradication

Usually, the following 3 drugs are orally administered at the same time twice daily for 7 days: 20 mg vonoprazan, 750 mg amoxicillin, and 200 mg clarithromycin. The dose of clarithromycin may be appropriately increased as required, however, the upper limit is 400 mg twice daily. When Helicobacter pylori eradication treatment with 3 drugs consisting of a proton pump inhibitor, amoxicillin, and clarithromycin fails, alternative treatment with the following 3 drugs is recommended: 20 mg vonoprazan, 750 mg amoxicillin, and 250 mg metronidazole, orally administered at the same time twice daily for 7 days. The doses of antibiotic should follow the respective label recommendations for H. pylori eradication.

Method of administration

Vonoprazan can be taken without regard to food or timing of food.

4.3 Contraindications

Hypersensitivity to the active ingredients or to any of the excipients.

4.4 Special warnings and precautions for use

Hepatotoxicity

Hepatic function abnormalities including liver injury have been reported in clinical studies (see section 4.8). Post marketing reports have also been received in patients treated with vonoprazan, many of which occurred shortly after initiation of treatment. Discontinuation of vonoprazan is recommended in patients who have evidence of liver function abnormalities or if they develop signs or symptoms suggestive of liver dysfunction.

Elevation of intragastric pH

Administration of vonoprazan results in elevation of intragastric pH and is therefore not recommended to be taken with drugs for which absorption is dependent on acidic intragastric pH.

Masking of symptoms associated with gastric malignancy

Gastric malignancy may present with symptoms associated with acid-related disorders which initially respond to drugs that elevate intragastric pH. A symptomatic response to vonoprazan does not exclude the presence of gastric malignancy.

***Clostridium difficile* associated diarrhea, including pseudomembranous colitis**

Drugs that elevate intragastric pH may be associated with an increased risk of *Clostridium difficile* gastrointestinal infection. Pseudomembranous colitis may be due to antibiotics used for *Helicobacter pylori* eradication in combination with vonoprazan. If abdominal pain and frequent diarrhea occur, appropriate measures, including discontinuation of the treatment, should be taken.

Bone fracture

An increased risk for osteoporosis-related fractures of the hip, wrist, or spine, predominantly in the elderly or in presence of other recognized risk factors, has been reported with the use of proton pump inhibitors, especially with use of high doses over a long-term period (>1 year). The mechanism is not clear and is likely to be multifactorial.

Renal impairment

Vonoprazan should be administered with care in patients with renal disorders as a delay in the excretion of vonoprazan may occur, which may result in an increase in the concentration of vonoprazan in the blood (see section 5.2).

Hepatic impairment

Vonoprazan should be administered with care in patients with hepatic disorders as a delay in the metabolism and excretion of vonoprazan may occur, which may result in an increase in the concentration of vonoprazan in the blood (see section 5.2).

Use in children

Vonoprazan has not been studied in patients under 18 years of age.

Use in the elderly

Since physiological functions such as hepatic or renal function are decreased in elderly patients in general, vonoprazan should be carefully administered (see Renal impairment and Hepatic impairment above).

4.5 Interaction with other medicinal products and other forms of interaction

Administration of vonoprazan results in elevation of intragastric pH, suggesting that it may interfere with the absorption of drugs where gastric pH is an important determinant of oral bioavailability. Use of vonoprazan is therefore not recommended with some of these drugs for which absorption is dependent on acidic intragastric pH such as atazanavir and nelfinavir, due to significant reduction in their bioavailability.

Vonoprazan is metabolized mainly by hepatic drug-metabolizing enzyme CYP3A4 and partially by CYP2B6, CYP2C19 and CYP2D6.

With strong CYP3A4 inhibitors, e.g. clarithromycin, blood concentration of vonoprazan may increase. It has been reported that blood concentration of vonoprazan increased in concomitant use with clarithromycin by 1.5-fold, but no dose adjustment of vonoprazan is considered necessary.

Coadministration of vonoprazan with the antibiotic regimen clarithromycin and amoxicillin increased concentrations of vonoprazan by up to 1.9-fold. No increase was observed with the antibiotic regimen of metronidazole and amoxicillin. No dose adjustment of vonoprazan is considered necessary.

There were no clinically significant effects of NSAIDs on the pharmacokinetics of vonoprazan, and no clinically significant effects of vonoprazan on the pharmacokinetics of NSAIDs.

Co-administration of midazolam (a sensitive CYP3A4 substrate) with multiple doses of vonoprazan increased concentration of midazolam by 1.9-fold in healthy subjects. Caution is advised when vonoprazan is co-administered with other sensitive CYP3A4 substrates, notably those having a narrow therapeutic index.

4.6 Fertility, pregnancy and lactation

Pregnancy

No clinical studies have been conducted to date to evaluate vonoprazan in subjects who are pregnant. In a rat toxicology study, embryo-foetal toxicity was observed following exposure of more than approximately 28 times of the exposure (AUC) at the maximum clinical dose (40 mg/day) of vonoprazan. As a precaution, vonoprazan should not be administered to women who are or may be pregnant, unless the expected therapeutic benefit is thought to outweigh any possible risk.

Lactation

No clinical studies have been conducted to date to evaluate vonoprazan in subjects who are lactating. It is unknown whether vonoprazan is excreted in human milk. In animal studies it has been shown that vonoprazan was excreted in milk. During treatment with vonoprazan, nursing should be avoided if the administration of this drug is necessary for the mother.

Fertility

No human fertility data are available (see section 5.3).

4.7 Effects on ability to drive and use machines

No data available.

4.8 Undesirable effects

The following convention is used for the classification of the frequency of an adverse drug reaction (ADR) and is based on the Council for

International Organizations of Medical Sciences (CIOMS) guidelines: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$); not known (cannot be estimated from the available data).

Clinical trials

Clinical trial data for expected adverse events is based on pooled safety analysis from the following studies: EE healing (CCT-001 and CCT-002), EE maintenance therapy (CCT-003 and OCT-001), GU healing (CCT-101), DU healing (CCT-102), prevention of recurrence of peptic ulcer associated with NSAID use (CCT-301, OCT-301 and OCT-303) and treatment of non-erosive reflux disease (NERD; CCT-201). Although the study in patients with NERD has a placebo arm and is considered the best data, the number of patients (N=449 and 278 for TAK-438 and placebo, respectively) is relatively small compared to the number of patients of all other active-comparator studies combined (N=3162 and 1392 for TAK-438 and AG-1749 [Lansoprazole], respectively). Therefore, the pooled safety data of active-comparator studies are used for the primary analysis. The safety data of the CCT-201 study are analyzed separately. (Note: AG-1749 (Lansoprazole) is the only comparator used in the comparator studies.)

Reporting of suspected adverse reactions: Healthcare professionals are asked to report any suspected adverse reactions via pharmacy and poisons board, Pharmacovigilance Electronic Reporting System (PvERS) <https://pv.pharmacyboardkenya.org>

4.9 Overdose

There is no experience of overdose with vonoprazan.

Vonoprazan is not removed from the circulation by hemodialysis. If overdose occurs, treatment should be symptomatic and supportive.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antacids, Antireflux Agents & Antiulcerants. ATC code: A02BC08.

Vonoprazan is a potassium competitive acid blocker (PCAB) and inhibits H^+ , K^+ -ATPase in a reversible and potassium-competitive manner. It does not require activation by acid. Vonoprazan is a strong base with a high affinity for the acid pump of gastric cells, inhibiting gastric acid production.

Serum gastrin and serum pepsinogen effects

Increased serum gastrin and serum pepsinogen concentrations are physiological responses to treatment with acid suppression therapy, including vonoprazan. Increased serum gastrin and serum pepsinogen concentrations were reported with a higher incidence in the vonoprazan

treatment groups compared with lansoprazole treatment groups. Serum gastrin and serum pepsinogen concentrations returned to baseline over time upon discontinuation of vonoprazan. The increase in serum gastrin concentration occurred early in treatment with vonoprazan and remained stable for the remainder of treatment.

Clinical studies

The efficacy of vonoprazan has been demonstrated in a number of clinical studies across several indications including GU, DU, RE, prevention of GU/DU during NSAID administration and as an adjunct to H. pylori eradication. These data are divided into categories based upon the specific indication, including GU, DU, RE, prevention of recurrence of gastric or duodenal ulcer during NSAID administration, and H. pylori eradication.

Following administration of vonoprazan at a dose of 10 mg or 20 mg in healthy adult male subjects for 7 days, pH 4 HTR (pH 4 holding time ratio, i.e. the percentage of time pH is maintained at a level ≥ 4 in 24 hours) was $63 \pm 9\%$ and $83 \pm 17\%$ respectively.

A phase 1 open-label pharmacodynamics study to investigate the acid-inhibitory effect of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole sodium 10 mg in healthy adult male Japanese subjects showed that the acid-inhibitory effect of vonoprazan was greater than that of esomeprazole or rabeprazole. After all treatments, the mean 24-hour pH 4 HTRs increased from Baseline to Day 1 and from Day 1 to Day 7. The mean pH 4 HTRs were higher after administration of vonoprazan on Day 1 than after administration of esomeprazole or rabeprazole on Day 7. The mean 24-hour pH 4 HTRs for vonoprazan and rabeprazole at Baseline were both 8.9%, and on Day 1 and on Day 7 were 84.16% vs 26.29%, and 93.79% vs 65.09%, respectively.

5.2 Pharmacokinetic properties

Following 7-day repeat once daily doses of vonoprazan at doses of 10-40 mg in healthy adult male subjects, $AUC_{t,ss}$ and $C_{max,ss}$ increase in a slightly greater than dose proportional manner. Steady state has been reached by day 3 of administration, since the trough level of the blood concentration of vonoprazan is constant between day 3 and day 7 of administration. In addition, vonoprazan does not exhibit time-dependent pharmacokinetics.

Absorption

Absolute bioavailability has not been determined. Pharmacokinetic parameters of vonoprazan following single administration to healthy adult male subjects at 20 mg under fasting and fed conditions have been characterised.

Distribution

The mean binding rate is 85.2 to 88.0% when [14C] vonoprazan in the range of 0.1 to 10 µg/mL is added to human plasma (in vitro).

Metabolism

Vonoprazan is metabolized mainly by hepatic drug-metabolizing enzyme CYP3A4 and partially by CYP2B6, CYP2C19 and CYP2D6. Vonoprazan is also metabolized by sulfotransferase SULT2A1 (in vitro).

Vonoprazan exhibits a time-dependent inhibitory effect on CYP2B6, CYP2C19 and CYP3A4/5 (in vitro). In addition, vonoprazan shows a slight concentration-dependent inductive effect on CYP1A2, but it shows little inductive effect on CYP2B6 and CYP3A4/5 (in vitro).

Excretion and elimination

When radioactive-labeled drug (15 mg as vonoprazan) is orally administered to healthy adult male subjects, 98.5% of the radioactivity administered is excreted into urine and feces by 168 hours after administration: 67.4% into urine and 31.1% into feces.

Special populations — impaired renal function

The effect of renal disorders on pharmacokinetics of vonoprazan was evaluated in subjects with normal renal function and patients with mild, moderate or severe renal disorder and patients with end-stage renal disease (ESRD). When administered a single dose of vonoprazan 20 mg, the AUC_∞ was higher by 1.3 to 2.4 times and the C_{max} higher by 1.2 to 1.8 times in patients with mild, moderate or severe renal disorder compared to subjects with normal renal function, indicating an increase in vonoprazan exposure with a reduction in renal function. The AUC_∞ was higher by 1.3 times and the C_{max} higher by 1.2 times in ESRD patients compared to subjects with normal renal function.

Impaired hepatic function

The effect of hepatic disorders on pharmacokinetics of vonoprazan was evaluated in subjects with normal hepatic function and patients with mild, moderate or severe hepatic disorder. When administered a single dose of vonoprazan 20 mg, the AUC_∞ was higher by 1.2 to 2.6 times and C_{max} higher by 1.2 to 1.8 times in patients with mild, moderate or severe hepatic disorder compared to subjects with normal hepatic function.

Age, gender, race

Vonoprazan has not been studied in patients under 18 years of age. There are no clinically relevant gender effects of vonoprazan. No dedicated ethnic comparison studies have been conducted with vonoprazan. An ethnic sensitivity analysis based on the International Conference for Harmonization (ICH) E5 principles concluded that vonoprazan is insensitive to ethnic factor differences.

Drug interactions

Vonoprazan and clarithromycin: The AUC_{∞} and C_{max} of vonoprazan increased by 1.6 times and 1.4 times, respectively, when concomitantly administered with clarithromycin compared to vonoprazan administered alone.

Vonoprazan, amoxicillin and clarithromycin: Concomitant administration for 7 days shows no effect on pharmacokinetics of unchanged amoxicillin; however, AUC_{12} and C_{max} of vonoprazan increased by 1.8 times and 1.9 times, respectively, and AUC_{12} and C_{max} of unchanged clarithromycin increased by 1.5 times and 1.6 times, respectively.

Vonoprazan, amoxicillin and metronidazole: Concomitant administration for 7 days showed little difference in the pharmacokinetics of vonoprazan when administered alone or as triple therapy. No difference was observed in the pharmacokinetics of metronidazole or amoxicillin when administered alone or as triple therapy.

Vonoprazan and NSAIDs: No clear effect of NSAIDs on pharmacokinetics of vonoprazan, and no clear effect of vonoprazan on pharmacokinetics of NSAIDs, was observed.

Vonoprazan and midazolam: Steady-state plasma midazolam C_{max} and AUC_{∞} values were 93% and 89% higher, respectively, than when midazolam was administered alone. Steady-state plasma 1-hydroxymidazolam (main and active midazolam metabolite mediated by CYP3A4) C_{max} and AUC values were 25-37% higher than when midazolam was administered alone. Since midazolam systemic exposure increased less than 2-fold when co-administered with oral vonoprazan, vonoprazan is classified as a weak inhibitor of CYP3A4.

5.3 Preclinical safety data

Carcinogenesis

Vonoprazan was non-carcinogenic in a long-term carcinogenicity study in mice administered the drug daily via oral gavage for up to 2 years at 6, 20, 60, and 200 mg/kg/day. Treatment-related tumors, related to exaggerated pharmacology or species-specificity, were noted in the stomach and liver. In the stomach, benign and malignant neuroendocrine cell tumors were observed at ≥ 20 (males) and ≥ 60 (females) mg/kg/day and ≥ 6 (males) and ≥ 60 (females) mg/kg/day, respectively. In the liver, increased incidences of hepatocellular adenoma and carcinoma were observed at ≥ 20 (males) and ≥ 60 (females) mg/kg/day, and at ≥ 60 (males) and 200 (females) mg/kg/day, respectively. Hyperplasia of the neuroendocrine cells and associated tumors in the stomach may be due to hypergastrinemia as a consequence of inhibiting gastric acid secretion. The hepatocellular tumors are likely rodent-specific findings attributed to prolonged induction of hepatic drug-metabolizing enzymes. The NOAEL was < 6 mg/kg/day.

Vonoprazan was non-carcinogenic in a long-term carcinogenicity study in rats administered the drug via oral gavage at 5, 15, 50, and 150 mg/kg/day. Treatment-related tumors, related to exaggerated pharmacology or species-specificity, were noted in the stomach and liver. In the stomach, benign and malignant neuroendocrine cell tumors were observed at ≥ 5 mg/kg/day except for malignant neuroendocrine tumor at 50 mg/kg/day (males). In the liver, increased incidences of hepatocellular adenoma and carcinoma were observed at ≥ 50 mg/kg/day except for hepatocellular carcinoma at 50 mg/kg/day (females). Tumor findings in the stomach and liver are believed to be due to hypergastrinemia as a consequence of inhibiting gastric acid secretion and rodent-specific induction of hepatic drug-metabolizing enzymes, respectively. The occurrence of 4 hepatocholangiocellular tumors at ≥ 50 mg/kg/day (males) were considered treatment-related, associated with induction of hepatocellular tumor, though pairwise comparison did not demonstrate a statistically significant effect.

Mutagenicity

Vonoprazan did not exhibit any mutagenic or clastogenic activity in the in vitro Ames assay, in vitro mammalian chromosome aberration assay, and in vivo rat micronucleus assay.

Impairment of fertility

When administered daily via oral gavage to male and female rats, there were no effects on sperm analysis, estrous cycles or number of corpora lutea observed at doses up to 300 mg/kg/dose. Males were administered vonoprazan prior to and during mating and females dosed for 2 weeks pre-mating through Gestation Day (GD) 6. The NOAEL for male and female general toxicity was 30 mg/kg/day and ≥ 300 mg/kg/day for reproductive function and early embryonic development.

6. Pharmaceutical particulars

6.1 List of excipients

Mannitol BP
Microcrystalline Cellulose (Type 101) BP
Hypromellose (6 Cps) [HPMC] USP
Fumaric Acid USP NF
Croscarmellose Sodium USP NF
Magnesium Stearate BP
Opadry White (Y-1-7000) Ph. Gr.
Carnauba Wax BP
Purified Water BP

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store below 30°C. Protect from light. Keep out of the reach of children.

6.5 Nature and contents of container

Perforated Alu/Alu unit dose blisters in cartons containing 30 tablets.

6.6 Special precautions for disposal and other handling

No special requirements. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Aristopharma Ltd.

Plot # 14-22, Road # 11 & 12, Shampur-Kadamtali I/A, Dhaka-1204,
Bangladesh

Telephone: +880-2-9351691-93

Fax: +880-2-8317005

e-mail: parvez@aristopharmabd.com

8. Marketing authorisation number

H2024/CTD11628/24839

9. Date of first authorisation/renewal of the authorisation

24th October, 2024

10. Date of revision of the text

25th August, 2026